Why trials actually die: what 34,000 terminations reveal

A terminated trial is not an abstraction to the people who staffed it. It is a program that ended, a team that got reassigned or cut, and a line on a resume that now needs explaining. The public ClinicalTrials.gov registry records every termination and, for most of them, why. We pulled the reasons across 4,000 terminated industry trials to see what actually kills the work. The answer is worth knowing before it happens to yours.

The registry, as of this pull

Of roughly 595,000 registered studies, about 34,000 are marked terminated and another 16,600 withdrawn before they ever enrolled a patient. That is a large graveyard, and industry sponsors fill a meaningful share of it. Among the terminated industry trials that stated a reason, the breakdown is consistent and revealing.

Enrollment is the number one killer

Roughly a quarter of terminated industry trials that gave a reason, about 25 percent, cited recruitment or enrollment: too few patients, too slow, sites that could not fill. It is the single largest named cause, larger than safety and larger than the drug not working. Sit with that. The most common reason a trial dies is not that the science failed. It is that not enough people enrolled.

For anyone who works in or near sites, that is your daily reality showing up in the mortality data. Enrollment is the grind, and it is also the thing that ends programs. The next four causes, in order: business or strategic decisions at about 15 percent (the sponsor reprioritized its portfolio), safety or risk-benefit at about 13 percent, efficacy or futility at about 10 percent (the drug did not clear its interim bar), and administrative or sponsor decisions at about 7 percent. Funding, the reason people assume, is under 2 percent for industry trials, because a large sponsor rarely runs out of money. It runs out of patience.

Withdrawn trials tell a different story

The trials that were withdrawn before enrolling anyone shift the mix. There, business and strategic reasons tie with recruitment at the top, each around 16 to 17 percent. A withdrawn trial is often a program the sponsor killed on paper before it started, which is why strategic decisions loom larger. The lesson: a lot of clinical work disappears at the planning stage, invisibly, before a single CRA is assigned.

What it means for your job

Two practical reads. First, if you want to protect your role, protect enrollment. The functions that make sites recruit faster, feasibility, site selection, patient-facing coordination, are working on the exact problem that kills the most trials. That is leverage. Second, when a program you are on starts missing enrollment targets, the registry data says you are looking at the most common precursor to termination. That is not doom, but it is a signal to read early, not late.

The number the registry cannot give you

The registry tells you a trial was terminated and why the sponsor said so. It does not tell you what happened to the people. Did the CRA team get moved to another study or let go? Did the biostatisticians ride it out? Was there severance? Those outcomes are the part that matters to a career, and they exist only with the people who lived them. If a terminated trial reshaped your job, that is the data the public record is missing. Post what you can, and add your compensation datapoint. The registry has the death certificate. You have the story.